Centre for Addiction and Mental Health

Quick facts

Marketed products

• Apo-Oxycodone CR®
• Aripiprazole Augmentation · Psychiatry / Mental Health
  Aripiprazole augmentation enhances the efficacy of antidepressants by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, improving mood regulation in treatment-resistant depression.
• Bupropion Augmentation
• Dexedrine · Other
• Lithium Augmentation · Psychiatry / Mental Health
  Lithium augmentation enhances the efficacy of antidepressant medications by potentiating serotonergic and noradrenergic neurotransmission in the brain.
• Nabilone Oral Capsule · Oncology; Pain Management; Psychiatry
  Nabilone is a synthetic cannabinoid that mimics THC by binding to cannabinoid receptors in the central nervous system to produce antiemetic and analgesic effects.
• Nicotine Replacement Therapy Agent
• OxyNEO® · Pain Management
  OxyNEO is an extended-release formulation of oxycodone designed to deter abuse by resisting crushing, dissolving, and extraction while maintaining analgesic efficacy.
• Placebo plus clinical management · Psychiatry/Addiction Medicine
  Placebo plus clinical management provides psychological benefit through expectation effects combined with structured clinical support and therapeutic interaction.
• Switch to bupropion · Psychiatry / Mental Health
  Bupropion is an atypical antidepressant that inhibits the reuptake of norepinephrine and dopamine, increasing their availability in the brain.
• Switch to nortriptyline · Psychiatry / Mental Health
  Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at neuronal synapses, increasing their availability in the central nervous system.
• Tobacco · Other

Phase 2 pipeline

• Corticotropin-Releasing Hormone · Psychiatry
  Corticotropin-Releasing Hormone stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland, which in turn increases cortisol production.
• Motherwell · Other

Phase 1 pipeline

• Cannabis tobacco
• Existing depression medication treatment
• ipratropium bromide 0.03% spray
• non-alcoholic beverage

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Centre for Addiction and Mental Health portfolio CI brief
• Centre for Addiction and Mental Health pipeline updates RSS

Frequently asked questions about Centre for Addiction and Mental Health

Related

• Apo-Oxycodone CR®
• Aripiprazole Augmentation · Psychiatry / Mental Health
• Bupropion Augmentation
• Dexedrine · Other
• Lithium Augmentation · Psychiatry / Mental Health
• Sector hub: All tracked pharma companies